"目錄號: HY-15231

Anti-infection-

PSI-352938 是一種丙型肝炎病毒 (HCV) 核苷酸抑制劑。

HCV

相關(guān)產(chǎn)品

Asunaprevir-PSI-7977-Simeprevir-Daclatasvir-Paritaprevir-Telaprevir-Boceprevir-Ledipasvir-Ombitasvir-MK-5172-Elbasvir-ABT-333-Ribavirin-R-1479-Balapiravir-

生物活性

Description

PSI-352938 is a hepatitis C virus (HCV) nucleotide inhibitor.

IC50& Target

HCV

In Vitro

PSI-352938 and PSI-353661 inhibit HCV genotype (GT) 1b replicon replication with 50% effective concentrations (EC50s) of 0.13±0.076 μM and 3.0±1.4 nM, respectively, and are similarly active against GT 1a and 2a replicons and infectious viruses. Metabolism of PSI-352938 and PSI-353661 generates the same 5′-triphosphate metabolite, PSI-352666, which is similarly active against NS5B polymerases from GT 1 to 4[1]. PSI-352938 is a novel cyclic phosphate prodrug of β-D-2′-deoxy-2′-α-fluoro-2′-β-C-methylguanosine 5′-monophosphate that has potent activity against HCV. PSI-352938 has similar activity against genotype 1a, 1b, and 2a replicons, with EC50s ranging from 0.13 to 0.20 μM and EC90values ranging from 0.35 to 0.74 μM. PSI-352938 also effectively inhibits HCV replication in the infectious virus assays: the EC50and EC90values are 0.28±0.083 μM and 0.63±0.018 μM, respectively, against the H77 infectious virus and 0.39±0.31 μM and 1.16±0.64 μM, respectively, against the JFH-1 infectious virus. In contrast, PSI-352938 is not active against HBV or HIV up to the highest concentration tested (EC50>100 μM)[2].

Clinical Trial

NCT01497327

Gilead Sciences

Hepatitis C

July 2011

Phase 1

View MoreCollapse

References

[1].Lam AM, et al. Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA. J Virol. 2011 Dec;85(23):12334-42.

[2].Lam AM, et al. Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine. Antimicrob Agents Chemother. 2011 Jun;55(6):2566-75.